NAVROGEN ANNOUNCES THE CLOSING OF $3.2M FUNDING TO SUPPORT ITS HUMORAL IMMUNO-ONCOLOGY PLATFORM DISCOVERY TECHNOLOGIES AND PRECLINICAL PIPELINE

Philadelphia, PA, September 17, 2019 -- Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing was led by Ben Franklin Technology Partners of South Eastern Pennsylvania and a number of private investors. 

read more